Arcturus Therapeutics is trading at $13.05, down 5.01%, with no clear company-specific announcement or catalyst identified for the October 12 decline.
- Leerink reiterated its Outperform rating and raised its price target to $19 on October 9; that earlier positive action does not explain the drop.
- The broader market was mixed, with the Nasdaq down 0.41%, which does not establish a market-wide cause.
- Intraday volume or activity details were not available.